184P - The efficacy and safety of amrubicin in non-small-cell lung cancer patients beyond third-line therapy

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Anticancer Agents
Non-Small Cell Lung Cancer
Biological Therapy
Presenter Mika Saigusa
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors M. Saigusa, S. Sakurai, T. Akamatsu, A. Yamamoto, Y. Shishido, T. Akita, S. Morita, K. Asada, T. Shirai, T. Eto
  • Respiratory Medicine, Shizuoka General Hospital, 4208527 - Shizuoka/JP



There are no standard cytotoxic treatments for non-small-cell lung cancer (NSCLC) patients beyond third-line therapy. Amrubicin (AMR), a third-generation synthetic anthracyclin agent, is used to treat small-cell lung cancer patients. Recently, several clinical trials have shown the efficacy and safety of AMR for advanced NSCLC patients. The purpose of this study is to evaluate the efficacy and safety of AMR in pretreated NSCLC patients.


The records of NSCLC patients who received AMR monotherapy as a third or later line of chemotherapy at Shizuoka General Hospital between April 2007 and March 2014 were retrospectively reviewed. Tumor response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.


Sixty-nine patients received AMR for NSCLC as beyond third-line therapy; 16 were female, and median age was 67 (39–81). The median number of treatment cycles was 3 (range, 1–24). The response rate was 7.2%, and the disease control rate was 63.8%. Median progression-free survival time was 2.8 months. Median survival time from the start of AMR was 7.7 months. The frequencies of ≥ grade 3 hematologic toxicities were 59.4% for leukopenia, 62.3% for neutropenia, 24.6% for anemia, 10.1% for thrombocytopenia, and 13.0% for febrile neutropenia. The frequencies of ≥ grade 2 non-hematologic toxicities were 27.5% for anorexia, 24.6% for fatigue, 17.4% for nausea, 15.9% for constipation, and 2.9% for rash. No treatment-related death was observed.


Although hematologic toxicities were severe, these results suggest that AMR in NSCLC patients beyond third-line therapy shows sufficient clinical benefit.

Clinical trial identification

Legal entity responsible for the study

Respiratory Medicine, Shizuoka General Hospital


Respiratory Medicine, Shizuoka General Hospital


All authors have declared no conflicts of interest.